P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

• Published in: Journal of personalized medicine 2021-03, Vol.11 (3), p.222
• Main Authors: Park, Sohyun, Choi, Yeo Jin, Kang, Ji Eun, Kim, Myeong Gyu, Jung Geum, Min, Kim, So Dam, Rhie, Sandy Jeong
• Format: Article
• Language: English
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm11030222

This study aims to evaluate potentially appropriate antiplatelet therapy in patients with chronic kidney disease. A systematic analysis was conducted to identify the clinical outcomes of available antiplatelet therapy regimens with enhanced platelet inhibition activity (intervention of 5 regimens) over the standard dose of clopidogrel-based dual antiplatelet therapy in patients with renal insufficiency. An electronic keyword search was performed on Pubmed, Embase, and Cochrane Library per PRISMA guidelines. We performed a prespecified net clinical benefit analysis (a composite of the rates of all-cause or cardiac-related death, myocardial infarction, major adverse cardiac outcomes, and minor and major bleeding), and included 12 studies. The intervention substantially lowered the incidence of all-cause mortality (RR 0.67; = 0.003), major adverse cardiac outcomes (RR 0.79; < 0.00001), and myocardial infarction (RR 0.28; = 0.00007) without major bleeding (RR 1.14; = 0.33) in patients with renal insufficiency, but no significant differences were noticed with cardiac-related mortality and stent thrombosis. The subgroup analysis revealed substantially elevated bleeding risk in patients with severe renal insufficiency or on hemodialysis (RR 1.68; = 0.002). Our study confirmed that the intervention considerably enhances clinical outcomes in patients with renal insufficiency, however, a standard dose of clopidogrel-based antiplatelet therapy is favorable in patients with severe renal insufficiency.